clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

This type affects 1 in 20 people with lymphoma and is more common in older adults and men. It forms in your spleen, lymph nodes, or bone marrow. Mantle cell lymphoma grows slowly but can be hard ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

In the BRIGHT study, bendamustine plus rituximab was evaluated as a first-line treatment for indolent non-Hodgkin lymphoma or mantle cell lymphoma compared with a standard rituximab-chemotherapy ...

Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma, and lowers the compounding preparation process needed for administration. A proteasome ...